• Policy
• Next year's new drug R&D budget: 58 billion won
• by Lee, Jeong-Hwan Sep 8, 2023 05:34am

• Policy
• Advanced biologics to receive expedited review
• by Lee, Hye-Kyung Sep 8, 2023 05:33am

• Policy
• Yooyoung will newly release repackaged flagship Pravafenix
• by Lee, Tak-Sun Sep 7, 2023 03:50pm

• Policy
• MFDS amends medical device permit renewal regulations
• by Lee, Hye-Kyung Sep 7, 2023 05:31am

• Policy
• What to expect from the upcoming 2-day HIRA DREC meeting
• by Lee, Tak-Sun Sep 7, 2023 05:31am

• Policy
• Daewoong withdraws its Herceptin biosimilar Ogivri from mkt
• by Lee, Hye-Kyung Sep 6, 2023 05:36am

• Policy
• What about digital therapy devices awaiting approval
• by Lee, Hye-Kyung Sep 6, 2023 05:36am

• Policy
• Reimb of HA eye drops will be restricted in KOR
• by Lee, Tak-Sun Sep 6, 2023 05:36am

• Policy
• Evaluating Tagrisso's primary benefit
• by Lee, Jeong-Hwan Sep 5, 2023 05:40am

• Policy
• Drug crime regulation,
• by Lee, Jeong-Hwan Sep 5, 2023 05:40am